Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

berlis ag - ethinylestradiolum, cyproteroni acetas - dragées - ethinylestradiolum 35 µg, cyproteroni acetas 2 mg, lactosum monohydricum 31.115 mg, maydis amylum, povidonum k 25, talcum, magnesii stearas, Überzug: saccharum 19.371 mg, povidonum k 90, macrogolum 6000, calcii carbonas, talcum, glycerolum (85 per centum), cera montana, e 171, e 172 (flavum), pro compresso. - manifestations androgéniques - synthetika

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

stragen pharma sa - cyproteroni acetas, ethinylestradiolum - dragées - cyproteroni acetas 2 mg, ethinylestradiolum 0.035 mg, lactosum monohydricum 31.115 mg, maydis amylum, povidonum k 25, magnesii stearas, talcum, pellicule: talcum, saccharum 19.637 mg, calcii carbonas, macrogolum 6000, e 171, povidonum k 90, glycerolum (85 per centum), cera montanglycoli, pro compresso obducto. - manifestations d'hyperandrogénie - synthetika

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - ethinylestradiolum, cyproteroni acetas - dragées - ethinylestradiolum 35 µg, cyproteroni acetas 2 mg, lactosum monohydricum 41.19 mg, cellulosum microcristallinum, povidonum k 30, carmellosum natricum conexum corresp. natrium 0.016 mm, magnesii stearas, Überzug: hypromellosum, e 171, macrogolum 400, e 132, e 172 (flavum), e 172 (nigrum), e 172 (rubrum), e 104, lacca, cera alba, cera carnauba, saccharum 10.36 mg, pro compresso obducto. - manifestations androgéniques - synthetika

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - ethinylestradiolum, cyproteroni acetas - dragées - ethinylestradiolum 35 µg, cyproteroni acetas 2 mg, color.: e 104, e 132, excipiens pro compresso de la brume. - manifestations androgéniques - synthetika

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

effik sa - cyproteroni acetas, ethinylestradiolum - comprimé pelliculé - cyproteroni acetas 2 mg, ethinylestradiolum 35 µg, lactosum monohydricum 29.115 mg, maydis amylum, povidonum k 25, talcum, magnesii stearas, saccharum 19.637 mg, calcii carbonas, povidonum k 90, macrogolum 6000, glycerolum (85 per centum), cera montanglycoli, e 171, e 172, pro compresso obducto. - manifestations d'hyperandrogénie - synthetika

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

dermapharm ag - ethinylestradiolum, cyproteroni acetas - dragées - ethinylestradiolum 0,035 mg, cyproteroni acetas 2 mg, lactosum monohydricum 47.165 mg, maydis pour amylum, maltodextrinum, magnésium stearas, Überzug: hypromellosum, lactosum monohydricum 0.272 mg, macrogolum 4000, natrii citras dihydricus, macrogolum 400, e 104, e 171, e 172 (rouge) e 172 (jaune) e 172 (noir), pour compresso haze corresp. sodium 0,0083 mg. - manifestations androgéniques - synthetika

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

gynial ag - ethinylestradiolum, cyproteroni acetas - enduits de comprimé - ethinylestradiolum 0,035 mg, cyproteroni acetas 2 mg, lactosum monohydricum 47.165 mg, maydis pour amylum, maltodextrinum, magnésium stearas, Überzug: hypromellosum, lactosum monohydricum 0.272 mg, macrogolum 4000, natrii citras dihydricus, macrogolum 400, e 104, e 171, e 172 (rouge) e 172 (jaune) e 172 (noir), pour compresso haze corresp. sodium 0,0083 mg. - manifestations androgéniques - synthetika

Belgium - French - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gedeon richter plc - ethinylestradiol 0,02 mg; gestodène 0,075 mg - comprimé enrobé - 0,020 mg - 0,075 mg - ethinylestradiol 20 µg; gestodène 75 µg - gestodene and ethinylestradiol

Belgium - French - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gedeon richter plc - ethinylestradiol 0,03 mg; gestodène 0,075 mg - comprimé enrobé - 75 µg - 30 µg - ethinylestradiol 30 µg; gestodène 75 µg - gestodene and ethinylestradiol

European Union - French - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - cellule précurseur leucémie lymphoblastique - lymphome - agents antinéoplasiques - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.